Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
BACKGROUND
Temporomandibular disorders (TMDs) are characterized by persistent orofacial pain and have diverse etiologic factors that are not well understood. It is thought that central sensitization leads to neuronal hyperexcitability and contributes to hyperalgesia and spontaneous pain. Nonsteroidal anti-inflammatory drugs (NSAIDs) are currently the first choice of drug to relieve TMD pain. NSAIDS were shown to exhibit anticonvulsant properties and suppress cortical neuron activities by enhancing neuronal voltage-gated potassium KCNQ/Kv7 channels (M-current), suggesting that specific activation of M-current might be beneficial for TMD pain.


RESULTS
In this study, we selected a new anticonvulsant drug retigabine that specifically activates M-current, and investigated the effect of retigabine on inflammation of the temporomandibular joint (TMJ) induced by complete Freund's adjuvant (CFA) in rats. The results show that the head withdrawal threshold for escape from mechanical stimulation applied to facial skin over the TMJ in inflamed rats was significantly lower than that in control rats. Administration of centrally acting M-channel opener retigabine (2.5 and 7.5 mg/kg) can dose-dependently raise the head withdrawal threshold of mechanical allodynia, and this analgesic effect can be reversed by the specific KCNQ channel blocker XE991 (3 mg/kg). Food intake is known to be negatively associated with TMJ inflammation. Food intake was increased significantly by the administration of retigabine (2.5 and 7.5 mg/kg), and this effect was reversed by XE991 (3 mg/kg). Furthermore, intracerebralventricular injection of retigabine further confirmed the analgesic effect of central retigabine on inflammatory TMJ.


CONCLUSIONS
Our findings indicate that central sensitization is involved in inflammatory TMJ pain and pharmacological intervention for controlling central hyperexcitability by activation of neuronal KCNQ/M-channels may have therapeutic potential for TMDs.
Xu
Wen
W
Department of Neurobiology, Neuroscience Research Institute, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100191, China.
Wu
Yuwei
Y
Bi
Yeping
Y
Tan
Lei
L
Gan
Yehua
Y
Wang
Kewei
K
D000698:Analgesia; D000818:Animals; D000873:Anthracenes / Q000494:pharmacology; D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002219:Carbamates / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D005247:Feeding Behavior / Q000187:drug effects; D005620:Freund's Adjuvant; D006930:Hyperalgesia / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D007249:Inflammation / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D007276:Injections, Intraventricular; D015640:Ion Channel Gating / Q000187:drug effects*; D051656:KCNQ Potassium Channels / Q000378:metabolism*; D008297:Male; D010655:Phenylenediamines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D013704:Temporomandibular Joint / Q000187:drug effects / Q000473:pathology* / Q000503:physiopathology
C112297:10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone; D000873:Anthracenes; D000927:Anticonvulsants; D002219:Carbamates; D051656:KCNQ Potassium Channels; D010655:Phenylenediamines; C101866:ezogabine; D005620:Freund's Adjuvant
Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52
18590620
Nature. 1980 Feb 14;283(5748):673-6
6965523
Cells Tissues Organs. 2005;180(1):69-75
16088135
Pharmacol Biochem Behav. 2003 Apr;75(1):181-9
12759126
J Am Pharm Assoc (Wash). 1998 May-Jun;38(3):354-61; quiz 362-3
9654866
Arch Neurol. 2003 Apr;60(4):496-500
12707061
Pain. 2005 Aug;116(3):375-385
15985331
Oral Maxillofac Surg Clin North Am. 2008 May;20(2):197-210, vi
18343325
Naunyn Schmiedebergs Arch Pharmacol. 2004 Apr;369(4):382-90
15007538
Neuroscience. 2006;138(2):621-30
16387448
J Am Dent Assoc. 1996 May;127(5):581-93
8642138
Nat Genet. 1998 Jan;18(1):53-5
9425900
J Oral Maxillofac Surg. 1991 Nov;49(11):1159-61; discussion 1162
1941329
Neuropharmacology. 2008 Jun;54(8):1271-8
18474382
Neurosci Lett. 2007 Feb 14;413(2):159-62
17184917
Eur J Pharmacol. 2003 Jan 24;460(2-3):109-16
12559370
Mol Pharmacol. 2005 Apr;67(4):1053-66
15598972
Neuropharmacology. 2001 Jun;40(7):888-98
11378159
Neurosci Lett. 2000 Mar 17;282(1-2):73-6
10713399
Pain. 2007 Jan;127(1-2):151-60
17030096
Br J Pharmacol. 2009 Apr;156(8):1185-95
19298256
Pain. 2008 Sep 15;138(3):537-545
18331780
Epilepsia. 2000 Jan;41(1):28-33
10643920
Br J Pharmacol. 2001 Jan;132(2):381-4
11159685
J Neurosci. 2010 Jun 30;30(26):8710-9
20592193
J Oral Rehabil. 2008 Oct;35(10):729-38
18482350
J Orofac Pain. 2004 Winter;18(1):41-55
15029872
J Neurosci. 2003 Aug 6;23(18):7227-36
12904483
Eur J Pharmacol. 2004 Mar 8;487(1-3):93-103
15033380
Science. 1998 Dec 4;282(5395):1890-3
9836639
Physiol Behav. 1999 Nov;67(5):711-6
10604842
Science. 1998 Jan 16;279(5349):403-6
9430594
Prog Biophys Mol Biol. 2000;73(2-4):135-66
10958929
J Oral Maxillofac Surg. 1998 Feb;56(2):189-91
9461143
J Dent Res. 2000 Sep;79(9):1704-11
11023267
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Sep;100(3):308-14
16122658
Neurosci Lett. 2006 May 29;400(1-2):101-4
16513263
J Neurosci. 2001 Dec 15;21(24):9529-40
11739564
J Biol Chem. 2000 Aug 4;275(31):24089-95
10816588
Nat Neurosci. 2005 Jan;8(1):51-60
15608631
J Steroid Biochem Mol Biol. 2005 Nov;97(3):241-50
16153820
J Neurophysiol. 2005 May;93(5):2723-38
15625101
J Prosthet Dent. 1989 Jul;62(1):61-5
2746544
Acta Odontol Scand. 2006 Aug;64(4):221-6
16829497
J Oral Maxillofac Surg. 1997 Mar;55(3):210-7; discussion 217-8
9054908
Eur J Pharmacol. 1997 Oct 8;336(2-3):243-9
9384239
Epilepsy Res. 1996 Apr;23(3):211-23
8739124
J Urol. 2004 Nov;172(5 Pt 1):2054-8
15540788